The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective

Affiliations

Editorial

Steven E Schild. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S294.

doi: 10.21037/atm.2019.11.42.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Theelen WSME, et al. JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478. JAMA Oncol. 2019. PMID: 31294749 Free PMC article.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. 10.3322/caac.21551 - DOI - PubMed
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. 10.1200/JCO.1995.13.1.8 - DOI - PubMed
1. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015;16:630-7. 10.1016/S1470-2045(15)70168-3 - DOI - PMC - PubMed
1. Hobbs CJ, Ko SJ, Paryani NN, et al. Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience. Mayo Clin Proc Innov Qual Outcomes 2017;2:40-8. 10.1016/j.mayocpiqo.2017.11.001 - DOI - PMC - PubMed
1. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-31. 10.1016/j.ijrobp.2005.05.034 - DOI - PubMed